Digital-Native Approach
We integrate digital twin technology, real-time data environments, and AI-augmented process modelling into every programme, helping sponsors assess and select CDMOs with genuine digital maturity.
CENDARA Bioscience embeds expert resource across your sponsor–CDMO interface from Phase 1 through commercial readiness – compressing timelines by 30–60% and charging only when we deliver. We eliminate the wasted months that cost pharmaceutical companies tens of millions of dollars between outsourcing decision and full-speed programme execution.
We integrate digital twin technology, real-time data environments, and AI-augmented process modelling into every programme, helping sponsors assess and select CDMOs with genuine digital maturity.
How CENDARA Closes the Gap
01
We run experiments in parallel rather than sequentially, building CMC regulatory strategy alongside the science from day one.
02
Our embedded resource ensures development learnings are captured systematically and applied at scale, reducing tech transfer risk by up to 50%.
03
We architect governance, data-sharing protocols, and KPI baselines before CDMO selection, eliminating downstream rework and compliance surprises.
From exclusive mandate through verified timeline savings, our no-risk model ensures alignment between sponsor and advisory at every stage.
Sponsors pay nothing upfront. Placement fees are charged to the CDMO; performance bonuses are triggered only by verified time savings. We absorb the risk and earn by delivering.
We do not deliver a report and step away. Our specialists sit within the programme team, working alongside sponsor scientists and CDMO project managers every week.
We conduct four-week independent due diligence across a curated panel of 8–12 best-in-class CDMOs with no preferred partners, no sponsorship bias, and no hidden incentives.
The question for every sponsor is not whether to accelerate – it is how quickly they choose to begin.
+44 (0) 1244 26 7676
© 2026 CENDARA Bioscience. All rights reserved.